Klivira
Request demo

Navigating Anthem (Elevance Health) Briumvi Prior Authorization

Efficiently managing **Anthem (Elevance Health) Briumvi prior authorization** is critical for timely patient access to this anti-CD20 monoclonal antibody for relapsing multiple sclerosis.

For revenue cycle directors and prior authorization coordinators, understanding the specific requirements for high-volume specialty drugs like Briumvi under Anthem-licensed plans is essential. This guide outlines the key pathways and considerations for obtaining prior authorization from Anthem (Elevance Health).

Briumvi Prior Authorization Submission Channels for Anthem

As an anti-CD20 monoclonal antibody administered via infusion, Briumvi typically falls under the medical benefit for Anthem-licensed plans. Medical-benefit prior authorization requests for commercial and Medicare Advantage lines are primarily submitted through Availity Essentials, Anthem's multi-payer provider workspace. Additionally, X12 278 transactions are accepted via clearinghouses for electronic submission.

Accessing Anthem's Medical Policies for Briumvi

Anthem operating companies publish their medical policies and clinical utilization management guidelines through provider sites, accessible via Availity. Each state-licensed Anthem plan maintains its own medical-policy index, which aligns with the Elevance Health corporate criteria framework, including state-specific Medicaid and Medicare Advantage variants. When referencing, ensure to cite the specific policy number, plan-state context, and effective date.

Key Utilization Management Considerations for Briumvi

For specialty injectables and infusions like Briumvi, Anthem's utilization management often focuses on clinical indication, medical necessity, and site-of-care policies. These policies are crucial for ensuring appropriate use and may influence where the infusion is approved to take place. Verifying the specific criteria within the applicable Anthem medical policy is a critical step in the prior authorization process.

Anticipating Denial Patterns and Appeal Pathways for Briumvi with Anthem

Common denial reasons for specialty drugs under Anthem include medical necessity, insufficient documentation, failure to meet step therapy requirements, and site-of-service mismatch given active site-of-care policies. Denials are typically communicated via X12 277/835 transactions or Availity status updates. Appeals for standard medical PA follow the Anthem operating-company appeals process, with peer-to-peer reviews available.

Electronic Prior Authorization (ePA) for Briumvi and Anthem

Elevance Health, through its Anthem operating companies, has participated in Da Vinci Project initiatives to advance electronic prior authorization. While specific SMART on FHIR PAS, CRD, and DTR conformance status requires verification of current public disclosures, Klivira's platform integrates with Anthem's established electronic channels, including X12 278 and Availity, to streamline medical benefit PA submissions for drugs like Briumvi.

Key Steps for Briumvi Prior Authorization with Anthem

  • Verify the specific Anthem medical policy and clinical guidelines for Briumvi (ublituximab) relevant to the patient's plan and state.
  • Gather comprehensive clinical documentation supporting the medical necessity and indication for relapsing multiple sclerosis.
  • Initiate the PA request via Availity Essentials or through X12 278 transactions with a connected clearinghouse.
  • Monitor PA status closely via Availity and be prepared to respond to requests for additional information.
  • If denied, prepare for an appeal following Anthem's documented appeal process, leveraging peer-to-peer review options.

Frequently asked questions

What is Briumvi used for?

Briumvi (ublituximab) is an anti-CD20 monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in adults. It targets specific B-cells believed to play a role in MS pathology.

How do I submit a Briumvi prior authorization request to Anthem?

For medical benefit Briumvi, submit prior authorization requests through Availity Essentials, Anthem's primary provider portal. Alternatively, X12 278 transactions are supported via clearinghouses. Ensure all required clinical documentation is attached to support medical necessity.

Where can I find Anthem's medical policy for Briumvi?

Anthem's medical policies for specialty drugs are available on their provider websites, typically accessed through Availity. It is crucial to locate the specific policy for Briumvi that corresponds to the patient's state and plan (e.g., commercial, Medicare Advantage, Medicaid managed care).

What are common reasons for Briumvi PA denials from Anthem?

Common denial reasons for Briumvi prior authorization from Anthem include insufficient clinical documentation, failure to meet medical necessity criteria, not completing required step therapy, or issues related to site-of-service policies, especially for infused medications.

Does Anthem (Elevance Health) support electronic prior authorization for Briumvi?

Anthem supports electronic prior authorization for medical benefit drugs like Briumvi through X12 278 transactions and their Availity portal. Elevance Health has also been involved in Da Vinci Project initiatives for broader ePA adoption. Klivira's platform integrates with these established electronic channels to facilitate efficient submissions.

Related coverage

Other briumvi prior authorization by payer

Other briumvi prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo